https://www.selleckchem.com/products/cc-122.html
53; 95% CI, 0.31-0.93). Heterogeneity and a paucity of eligible randomized controlled trials. Combination therapy with corticosteroids and IVIg may reduce mortality risks in patients with SJS/TEN overlap and TEN. Cyclosporine and etanercept are promising therapies, but more studies are required to provide clearer evidence. Combination therapy with corticosteroids and IVIg may reduce mortality risks in patients with SJS/TEN overlap and TEN. Cyclosporine and etanercept are promising therapies, but more studies are required to provide clear
Like
Comment
Share
